Another Eye Care blunder

OMG....this thread was so accurate. Look at the Durista Disaster!

 

Now the fun begins!

 

No more than 1 implant
Endothelial cell loss
Reimbursement issues
Run

 

What a screw up. Again. So now what? Three drop reps per territory? Layoffs? We’re being asked to sell this with indication of ONE implant for a LIFETIME in the hopes we get an expanded indication in TWO YEARS

 

Not sure there’s enough lipstick to dress up this pig

 

they dropped 3 reps?? Already?

 

They were saying 3 reps selling drops per territory. With everything new failing and patents on drops expiring in next 2-4 years means layoffs coming soon. Business can’t sustain that headcount for long

 

Chicken little!!!

 

Just math and common sense

 

And now a looming recession? So a practice is going to buy this stuff, buy it and pay extra to store it with uncertain reimbursement for a 1 lifetime implant with efficacy similar to timolol?

 

Welcome to the non-essential side huddle

 

This will be the first thing they scrap

You watch

 

Typical Allergan. Feel bad for these reps.

 

Even if it doesn’t happen who would keep this dead weight beyond 2021. Pilocarpine sketchy so what else? Abicopar?

 

True Tear!!!

 

The drug is decent. The delivery system is somewhat new. Problem- horrible approval from FDA. Why would anyone do this for a 12 week period and a elevated risk for endophthalmitis? Then add in the problems with managed care. Next issue is the sales team. Huge mistake to rest so heavy on pharma backgrounds in a buy & bill world. Rarely does the transition go well- same reason most surgical companies don't hire pharma reps en masse. Last problem is getting doctors to invest money in stocking. Maybe with a consignment program. And post covid19 when they are down 2 to 3 months of income and no surgical income. Doomed. Look at the glaucoma marketplace even when prostaglandins launched and were the "rage" they could never overtake the generic market. Now generic glaucoma meds at QD dosing and decent compliance this product is going to be pigeon- holed to those who have no use of their arms/hands or are experiencing dementia.

 

Irrelevant business

 

So now everyone is concerned over jumping ship on Restasis and glaucoma. Be happy.

 

Who’s jumping ship? We r lucky to have jobs with a strong franchise!

 

Please define strong franchise? Which products and how long patent runway in Eye Care. I agree lucky to have job but don’t lose all objective reasoning